Medical College of Wisconsin
This is a phase I, interventional, single-arm, open-label, dose-finding treatment study designed to evaluate the safety and preliminary efficacy of FT836 in combination with daratumumab in adult patients with relapsed and/or refractory myeloma who have failed prior therapies.
Inclusion Criteria: 1. Patients must ≥18 years and \< 80 years old. 2. Patients must have received \>=3 prior lines of therapies, including proteasome inhibitor, immunomodulator and a CD38 monoclonal antibody: • International Myeloma Working Group (IMWG) criteria define refractory disease as disease progression on or within 60 days of receiving therapy. 3. Patients must have measurable disease, including at least one or more of the following criteria: 1. Serum M-protein ≥ 0.5 g/dl; 2. Urine M-protein ≥ 200 mg/24 hrs; 3. Involved serum light chain ≥100 mg/L with abnormal light ch…
FT836 CAR T cells will be administered by IV injection.
FT836 CAR T cells will be administered by IV injection.
FT836 CAR T cells will be administered by IV injection.
Daratumumab will be administered intravenously.
Arctuva estimate
Verify or correct the compensation shown for this listing.